Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

4.1%

2 terminated/withdrawn out of 49 trials

Success Rate

91.3%

+4.8% vs industry average

Late-Stage Pipeline

8%

4 trials in Phase 3/4

Results Transparency

0%

0 of 21 completed trials have results

Key Signals

6 recruiting

Enrollment Performance

Analytics

N/A
30(81.1%)
Phase 2
3(8.1%)
Phase 3
3(8.1%)
Phase 4
1(2.7%)
37Total
N/A(30)
Phase 2(3)
Phase 3(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (49)

Showing 20 of 49 trials
NCT07462000Not ApplicableRecruiting

Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract

Role: lead

NCT07395180Not ApplicableActive Not Recruiting

Differentiation of Human Body Balance Disorders

Role: lead

NCT07350200Not ApplicableCompleted

XEN Glaucoma Implant for the Management of Operated Uncontrolled Glaucoma: Results and Complications During a Long-Term Follow-Up

Role: lead

NCT07257172Not ApplicableRecruiting

Sutureless Technique for Repositioning and Scleral Fixation of the Capsular Bag - Intraocular Lens Complex With Permanent Use of Iris Retractors

Role: lead

NCT06584266Recruiting

Multimodal Cardiac Imaging Registry in Patients with Atrial Fibrillation

Role: collaborator

NCT06389643Not ApplicableCompleted

Comparison of Safety and Efficacy of Four-Point Scleral Intraocular Lens Fixation and Yamane Techniques

Role: lead

NCT06183047Completed

Predictive Value of Early Changes of Chromogranin A Levels in Patients With Neuroendocrine Tumours Treated With PRRT

Role: lead

NCT06030661Unknown

The HF-POL Study - Multicenter Study of Polish Patients With HF and LVEF >40%

Role: collaborator

NCT06012552Phase 2Recruiting

Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19.

Role: lead

NCT03476590Not ApplicableCompleted

New Model of Care in Heart Failure

Role: lead

NCT05716880Phase 3Recruiting

Ketoanalogues for Muscle Mass Loss in Nephrotic Syndrome

Role: lead

NCT04558892Phase 2Terminated

Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.

Role: lead

NCT05516160Not ApplicableUnknown

Perceptually Calibrated Scale of Optical Aberrations

Role: lead

NCT04904341Phase 3Unknown

Efficacy of Cerebrolysin Treatment as an add-on Therapy to Mechanical Thrombectomy in Acute Ischemic Stroke.

Role: lead

NCT05365945Not ApplicableCompleted

Trunk Stabilization Exercises Affect the Activity of the Upper Limb

Role: lead

NCT05305898Phase 3Unknown

"MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome

Role: lead

NCT05108532Unknown

Polish Revision Obesity Surgery Study

Role: collaborator

NCT04695106Phase 4Recruiting

Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI

Role: collaborator

NCT04867564Unknown

Radiation-induced Cardiac Toxicity After Non-small Cell Lung Cancer Radiotherapy

Role: lead

NCT04926935Completed

Bloodstram Infections in ICU. Single Centre Observational Study.

Role: lead